Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05365451 · ClinicalTrials.gov registry record · Early Phase 1
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters
A Early Phase 1 study, sponsored by Washington State University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
NCT05365451 is a Early Phase 1 study that has completed, run by Washington State University. The registered enrollment target is 16 participants.
The verdict
NCT05365451, a Early Phase 1 study, has completed, sponsored by Washington State University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The objective of this study is to confirm the feasibility of using a panel of endogenous substrates/metabolites as a robust biomarker of OCTs and OATs by conducting a controlled, comprehensive clinical drug-drug interaction study in healthy adult volunteers. Metformin and furosemide will be used as probe drugs for OCTs and OATs, respectively; cimetidine and probenecid will be used as corresponding inhibitors. Results from this study will validate this novel approach, which will be extended to children by collaborators at Children's Mercy Hospital in Kansas City, MO.
Interventions
- DRUG MetFORMIN Oral Solution
- DRUG Cimetidine 400 MG
- DRUG Furosemide Oral Liquid Product
- DRUG Probenecid 500 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-04-11 |
| Est. Completion | 2023-07-22 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05365451
The ClinicalTrials.gov registry entry for NCT05365451 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington State University, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which MetFORMIN Oral Solution is the first listed.
NCT05365451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05365451 about?
NCT05365451 is a clinical study titled "Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters". The objective of this study is to confirm the feasibility of using a panel of endogenous substrates/metabolites as a robust biomarker of OCTs and OATs by conducting a controlled, comprehensive clinical drug-drug interaction study in healthy adult volunteers. Metformin and furosemide will be used as ...
What is the current status of trial NCT05365451?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2022-04-11. Estimated completion is 2023-07-22.
What interventions are being tested in trial NCT05365451?
The interventions under investigation include: MetFORMIN Oral Solution (DRUG), Cimetidine 400 MG (DRUG), Furosemide Oral Liquid Product (DRUG), Probenecid 500 MG (DRUG).
Who is sponsoring clinical trial NCT05365451?
This trial is sponsored by Washington State University, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.